Sign Out
Esketamine (Spravato) is indicated, in conjunction with oral antidepressant therapy, for treatment‑resistant depression (Major Depressive Disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current depressive episode).
Esketamine (Spravato) is indicated, in conjunction with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adult patients with Major Depressive Disorder who have acute suicidal ideation or behavior.
The effectiveness of Esketamine (Spravato) in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of Esketamine (Spravato) does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of Esketamine (Spravato).
